Pharmaceuticals

Spinal Muscular Atrophy Treatment Industry Poised for Rapid Growth, Forecast to Touch $10.38 Billion by 2030 at 15.2% CAGR

February 18, 2026February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the spinal muscular atrophy treatment market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Spinal Muscular Atrophy Treatment Market show for the 2026–2030 period?

The spinal muscular atrophy treatment market size has seen rapid expansion in recent years. It is projected to increase from $5.1 billion in 2025 to $5.89 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. The historical growth within this market can be attributed to factors such as limited therapeutic options for SMA, low awareness regarding genetic disorders, a reliance on hospital-based treatment, the slow adoption of innovative therapies, and an absence of early diagnosis programs.

The spinal muscular atrophy treatment market is anticipated to experience substantial growth in the coming years, with projections indicating it will reach $10.38 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 15.2%. This expected growth throughout the forecast period can be attributed to several factors, including the development of advanced gene therapies, increased investment in SMA research, the expansion of newborn screening initiatives, the rise of specialty clinics and homecare services, and the integration of digital health and telemedicine solutions. Key trends during this period are expected to include the rising adoption of gene therapy and SMN2 modifying treatments, a heightened focus on early diagnosis and newborn screening programs, the growth of homecare and specialty clinic-based SMA management, the expansion of multidisciplinary care teams for SMA patients, and the broader integration of telehealth and remote patient monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24714&type=smp

What Drivers Are Shaping The Development Of The Spinal Muscular Atrophy Treatment Market?

An increasing emphasis on gene therapy is projected to drive the expansion of the spinal muscular atrophy treatment market in the future. This medical technique entails altering an individual’s DNA or RNA to address or avert illnesses. The heightened attention to gene therapy stems largely from its capacity to tackle or resolve the underlying cause of genetic conditions through direct modification or replacement of defective genes, thereby providing enduring or permanent therapeutic outcomes versus conventional therapies. Specific spinal muscular atrophy treatments, like onasemnogene abeparvovec (Zolgensma), leverage gene therapy by offering a single-dose, targeted solution that introduces a working copy of the SMN1 gene, leading to substantial improvements in motor function and overall quality of life for patients with SMA. As an illustration, data from January 2024, released by the American Society of Gene and Cell Therapy, a US-based body dedicated to gene and cell therapy, indicated a 10% rise in the number of gene therapies undergoing Phase III trials during the fourth quarter of 2023 relative to the quarter prior. This marked the initial surge of this kind since the third quarter of 2022. Consequently, the increasing focus on gene therapy is fueling the growth of the spinal muscular atrophy treatment market.

Which Segments Are Contributing To The Growth Of The Spinal Muscular Atrophy Treatment Market?

The spinal muscular atrophy treatment market covered in this report is segmented –

1) By Treatment: Medication, Physical Therapy, Surgery, Other Treatments

2) By Type: Werdnig-Hoffmann Disease, Infant Spinal Muscular Atrophy, Kugelberg-Welander Disease, Adult Spinal Muscular Atrophy

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Medication: Nusinersen (Spinraza), Onasemnogene Abeparvovec-Xioi (Zolgensma), Risdiplam (Evrysdi), Antisense Oligonucleotides, Spinal Muscular Atrophy (SMN2) Splicing Modifiers, Corticosteroids, Supportive Medications

2) By Physical Therapy: Occupational Therapy, Respiratory Therapy, Aquatic Therapy, Orthotic Support, Assistive Mobility Devices, Range-Of-Motion Exercises

3) By Surgery: Spinal Fusion Surgery, Scoliosis Correction Surgery, Orthopedic Surgery, Gastrostomy Tube Placement, Tracheostomy

4) By Other Treatments: Nutritional Support, Respiratory Support, Psychosocial Support And Counseling, Genetic Counseling, Stem Cell Therapy

What Long-Term Trends Are Expected To Shape The Future Of The Spinal Muscular Atrophy Treatment Market?

Companies operating within the spinal muscular atrophy treatment market are primarily concentrating on developing innovative pharmaceutical compositions, such as survival motor neuron 2 (SMN2) splicing modifier tablets, to improve motor function and retard the advancement of the disease. These oral medications, survival motor neuron 2 (SMN2) splicing modifier tablets, are engineered to alter the splicing of the SMN2 gene, enabling the generation of functional SMN protein crucial for motor neuron survival. By elevating the levels of full-length SMN protein, these tablets aid in treating spinal muscular atrophy (SMA), subsequently enhancing muscle function and slowing the disease’s progression. For example, in February 2025, Genentech, Inc., a US-based biotechnology company, secured U.S. Food and Drug Administration approval for its Evrysdi (risdiplam) tablet, which stands as the inaugural and sole non-invasive SMN2 splicing modifier tablet for SMA treatment. The Evrysdi tablet delivers comparable effectiveness and safety to the existing oral solution, while also offering additional benefits like room-temperature storage and simpler administration for patients aged 2 years and older who weigh more than 44 lbs (20 kgs), thereby increasing convenience and adaptability in managing the illness.

Who Are The Primary Competitors In The Global Spinal Muscular Atrophy Treatment Market?

Major companies operating in the spinal muscular atrophy treatment market are F. Hoffmann-La Roche Ltd, Novartis AG, Biogen Inc., Ionis Pharmaceuticals Inc., Chugai Pharmaceutical Co. Ltd, PTC Therapeutics Inc., Voyager Therapeutics Inc., Scholar Rock Holding Corporation, Genethon, Exegenesis Bio Inc., Alcyone Therapeutics Inc., Biophytis SA, Ractigen Therapeutics, Sarepta Therapeutics Inc., Astellas Pharma Inc., Pfizer Inc., AstraZeneca PLC, Roche Molecular Systems Inc., Avexis Inc., Cytokinetics Incorporated, Repligen Corporation, Neurogene Inc., Solid Biosciences Inc., Entrada Therapeutics Inc., Regenxbio Inc., Rocket Pharmaceuticals Inc., Asklepios BioPharmaceutical (AskBio) Inc., Ultragenyx Pharmaceutical Inc., Catalyst Pharmaceuticals Inc., NMD Pharma A/S, Biohaven Pharmaceutical Holding Company Ltd, Vybion Inc., Apteeus SAS, BIOCAD INDIA PRIVATE LIMITED

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-treatment-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Spinal Muscular Atrophy Treatment Market?

North America was the largest region in the spinal muscular atrophy treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Spinal Muscular Atrophy Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24714&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Treatment Market 2026, By The Business Research Company

Spinal Surgery Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-surgery-devices-and-equipment-global-market-report

Cerebrospinal Fluid Management Csf Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cerebrospinal-fluid-management-csf-devices-and-equipment-global-market-report

Spinal Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/spinal-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795